I, Dwyer R, Dore GJ, Luo K, Kaldor JM Infection with HIV and hepatitis C virus among injecting drug customers in a prevention setting: retrospective cohort study. BMJ 317: 433437. 7. Maher L, Jalaludin B, Chant KG, Jayasuriya R, Sladden T, et al. Incidence and threat things for 1480666 hepatitis C seroconversion in injecting drug customers in Australia. Addiction 101: 14991508. 8. Remis R A study to characterize the epidemiology of hepatitis C infection in Canada, 2002. In: Public 56-59-7 price Overall health Agency of Canada, editor. Ottawa, ON: Public Wellness Agency of Canada. 9. Lelutiu-Weinberger C, Pouget ER, Des Jarlais DD, Cooper HL, Scheinmann R, et al. A meta-analysis of your hepatitis C virus distribution in diverse racial/ ethnic drug injector AKT inhibitor 2 site groups. Soc Sci Med 68: 579590. 10. Tyndall MW, Currie S, Spittal P Intensive injection cocaine use because the key danger aspect inside the Vancouver HIV epidemic. AIDS 17: 887893. 11. Valente TW, Vlahov D Selective risk taking amongst needle exchange participants: Implications for supplemental interventions. Amer J Public Overall health 91: 406411. 12. Marshall BD, Shoveller JA, Wood E, Patterson TL, Kerr T Difficulty accessing syringes mediates the partnership amongst methamphetamine use and syringe sharing among young injection drug customers. AIDS Behav 15: 15461553. 13. Patrick DM, Strathdee S, Archibald CP Determinants of HIV seroconversion in injection drug users through a time of increasing prevalence in Vancouver. Int J STD AIDS eight: 437445. 14. Strathdee SA, Patrick DM, Archibald CP Social determinants predict needle-sharing behaviour among injection drug customers in Vancouver, Canada. Addiction 92: 13391347. 15. Des Jarlais DC, T D, Perlis T, Vlahov D, Maslow C, et al. Variability within the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection amongst young injecting drug users in New York City. 157 157: 467471. 16. Vlahov D, Junge B The function of needle exchange programs in HIV prevention. Public Wellness Rep 113: 7580. 17. Bruneau J, Lamothe F, Franco E, Lachance N, Desy M, et al. Higher prices of HIV infection among injection drug users participating in needle exchange applications in Montreal: final results of a cohort study. Am J Epidemiol 146: 9941002. 18. Morissette C, Cox J, De P, Tremblay C, Roy E, et al. Minimal uptake of sterile drug preparation gear in a predominantly cocaine injecting population: implications for HIV and hepatitis C prevention. Int J Drug Policy 18: 204212. 19. Ouellet L, Huo D, Bailey SL HIV danger practices amongst needle exchange users and nonusers in Chicago. J Acquir Immune Defic Syndr 37: 11871196. 20. Burt RD, Hagan H, Garfein RS, Sabin K, Weinbaum C, et al. Trends in hepatitis B virus, hepatitis C virus, and human immunodeficiency virus prevalence, danger behaviors, and preventive measures amongst Seattle injection drug users aged 1830 years, 19942004. J Urban Overall health 84: 436454. 21. Shaw SY, Shah L, Jolly AM, Wylie JL Determinants of IDU syringe sharing: The relationship between availability of syringes and risk network member characteristics in Winnipeg, Canada. Addiction 102: 16261635. 22. Bluthenthal MA, Kral AH, Gee L, Erringer EA, Edlin BR The impact of syringe exchange use on high-risk injection drug customers: a cohort study. AIDS 14: 605611. 23. Neaigus A, Friedman S, Jose B, Goldstein M, Curtis R, et al. High-risk private networks and syringe sharing as danger components for HIV infection amongst new drug injectors. J Acquir Immune Defic Syndr Hum Retrovirol 11: 499509. 24. Sherman SG, Latkin.I, Dwyer R, Dore GJ, Luo K, Kaldor JM Infection with HIV and hepatitis C virus among injecting drug users inside a prevention setting: retrospective cohort study. BMJ 317: 433437. 7. Maher L, Jalaludin B, Chant KG, Jayasuriya R, Sladden T, et al. Incidence and threat elements for 1480666 hepatitis C seroconversion in injecting drug customers in Australia. Addiction 101: 14991508. 8. Remis R A study to characterize the epidemiology of hepatitis C infection in Canada, 2002. In: Public Wellness Agency of Canada, editor. Ottawa, ON: Public Health Agency of Canada. 9. Lelutiu-Weinberger C, Pouget ER, Des Jarlais DD, Cooper HL, Scheinmann R, et al. A meta-analysis of your hepatitis C virus distribution in diverse racial/ ethnic drug injector groups. Soc Sci Med 68: 579590. ten. Tyndall MW, Currie S, Spittal P Intensive injection cocaine use because the primary danger element inside the Vancouver HIV epidemic. AIDS 17: 887893. 11. Valente TW, Vlahov D Selective danger taking among needle exchange participants: Implications for supplemental interventions. Amer J Public Well being 91: 406411. 12. Marshall BD, Shoveller JA, Wood E, Patterson TL, Kerr T Difficulty accessing syringes mediates the partnership in between methamphetamine use and syringe sharing among young injection drug customers. AIDS Behav 15: 15461553. 13. Patrick DM, Strathdee S, Archibald CP Determinants of HIV seroconversion in injection drug users during a time of increasing prevalence in Vancouver. Int J STD AIDS 8: 437445. 14. Strathdee SA, Patrick DM, Archibald CP Social determinants predict needle-sharing behaviour among injection drug users in Vancouver, Canada. Addiction 92: 13391347. 15. Des Jarlais DC, T D, Perlis T, Vlahov D, Maslow C, et al. Variability within the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. 157 157: 467471. 16. Vlahov D, Junge B The part of needle exchange programs in HIV prevention. Public Overall health Rep 113: 7580. 17. Bruneau J, Lamothe F, Franco E, Lachance N, Desy M, et al. Higher rates of HIV infection among injection drug customers participating in needle exchange programs in Montreal: outcomes of a cohort study. Am J Epidemiol 146: 9941002. 18. Morissette C, Cox J, De P, Tremblay C, Roy E, et al. Minimal uptake of sterile drug preparation gear inside a predominantly cocaine injecting population: implications for HIV and hepatitis C prevention. Int J Drug Policy 18: 204212. 19. Ouellet L, Huo D, Bailey SL HIV risk practices among needle exchange customers and nonusers in Chicago. J Acquir Immune Defic Syndr 37: 11871196. 20. Burt RD, Hagan H, Garfein RS, Sabin K, Weinbaum C, et al. Trends in hepatitis B virus, hepatitis C virus, and human immunodeficiency virus prevalence, threat behaviors, and preventive measures among Seattle injection drug customers aged 1830 years, 19942004. J Urban Overall health 84: 436454. 21. Shaw SY, Shah L, Jolly AM, Wylie JL Determinants of IDU syringe sharing: The partnership involving availability of syringes and danger network member qualities in Winnipeg, Canada. Addiction 102: 16261635. 22. Bluthenthal MA, Kral AH, Gee L, Erringer EA, Edlin BR The effect of syringe exchange use on high-risk injection drug customers: a cohort study. AIDS 14: 605611. 23. Neaigus A, Friedman S, Jose B, Goldstein M, Curtis R, et al. High-risk personal networks and syringe sharing as danger elements for HIV infection amongst new drug injectors. J Acquir Immune Defic Syndr Hum Retrovirol 11: 499509. 24. Sherman SG, Latkin.
